Clostridium Difficile News and Research RSS Feed - Clostridium Difficile News and Research

Clostridium difficile is a type of bacterium found in human and animal waste. Clostridium difficile is a common cause of diarrhea that occurs in hospitals. It can also cause diarrhea or other intestinal disorders in patients treated with antibiotics.
Existing non-antibiotic therapeutic drugs could help combat antibiotic-resistant pathogens

Existing non-antibiotic therapeutic drugs could help combat antibiotic-resistant pathogens

The rise of antibiotic resistant bacterial pathogens is an increasingly global threat to public health. In the United States alone antibiotic resistant bacterial pathogens kill thousands every year. [More]
UC San Diego receives NIH grant to establish interdisciplinary center to combat antibiotic resistance

UC San Diego receives NIH grant to establish interdisciplinary center to combat antibiotic resistance

Researchers at University of California, San Diego School of Medicine have received a five-year, $9.5-million award from the National Institute of Allergy and Infectious Diseases at the National Institutes of Health to establish an interdisciplinary center to define the systems biology of antibiotic resistance. The program will be led by Bernhard Palsson, PhD, Distinguished Professor of Bioengineering and Pediatrics, and Victor Nizet, MD, professor of pediatrics and pharmacy. [More]
Novel antibiotics to overcome antibacterial resistance

Novel antibiotics to overcome antibacterial resistance

Small and innovative pharmaceutical companies, with products in early stages of development, presented some of their novel approaches and antimicrobial therapies under development during a dedicated session at the annual congress (ECCMID) of the European Society of Clinical Microbiology and Infectious Diseases(ESCMID) in Amsterdam. [More]
Fecal transplants transfer bacterial viruses that appear to be harmless to humans

Fecal transplants transfer bacterial viruses that appear to be harmless to humans

Communities of viruses can be transferred during fecal transplants, according to a study published this week in mBio, an online open-access journal of the American Society for Microbiology. Fortunately for patients who use this procedure, the viruses found to be transmitted in this study appear to be harmless to humans. [More]
Changing one atom in InsP6 inhibitor can increase its ability to neutralize toxins in the gut

Changing one atom in InsP6 inhibitor can increase its ability to neutralize toxins in the gut

Infections with bacterium Clostridium difficile have rapidly become a significant medical problem in hospitals and long-term care facilities. The bacteria cause diarrhea and life-threatening inflammation of the colon by producing toxins that kill the endothelial cells that form the lining of the gut. [More]
Valley Hospital, Holy Name Medical Center collaborate to defeat C. difficile

Valley Hospital, Holy Name Medical Center collaborate to defeat C. difficile

The Valley Hospital in Ridgewood, NJ, and Holy Name Medical Center in Teaneck, NJ, are collaborating to defeat a common foe: a dangerous drug-resistant bacterium called Clostridium difficile, or C. difficile. [More]
Allergan's sNDA for TEFLARO (ceftaroline fosamil) accepted by FDA

Allergan's sNDA for TEFLARO (ceftaroline fosamil) accepted by FDA

Allergan plc today announced the U.S. Food and Drug Administration has accepted for filing the company's supplemental New Drug Application (sNDA) for TEFLARO (ceftaroline fosamil). [More]
Discovery takes researchers one step closer to preventing C. diff

Discovery takes researchers one step closer to preventing C. diff

Exposure to specific antibiotics is linked to the development of certain strains of antibiotic-resistant C. difficile, one of the fastest growing bacteria superbugs, according to a new study published by Stuart Johnson, MD, of Loyola University Health System, Loyola University Chicago Stritch School of Medicine and the Hines VA Medical Hospital. [More]
CosmosID announces $6M in Series B funding round

CosmosID announces $6M in Series B funding round

CosmosID, the leading genomic big data company focused on microbiome research, outbreak investigations, and infectious disease diagnostics, using next-generation DNA sequencing, announced $6M in Series B funding. [More]
FDA approves Allergan's sNDA to update label for DALVANCE (dalbavancin) for injection

FDA approves Allergan's sNDA to update label for DALVANCE (dalbavancin) for injection

Allergan plc, a leading global pharmaceutical company, today announced the U.S. Food and Drug Administration has approved the company's supplemental new drug application (sNDA) to update the label for DALVANCE (dalbavancin) for injection. [More]
Mayo Clinic adds robots to prevent C-diff bacteria

Mayo Clinic adds robots to prevent C-diff bacteria

Mayo Clinic has added robots in its fight against Clostridium difficile (C-diff) bacteria. In the U.S., C-diff is one of the most common infections patients can get while receiving care at a health care facility. C-diff can cause a variety of symptoms, including potentially deadly diarrhea. A recent national report shows some progress in reducing C-diff infections; however, more work remains. [More]
Frozen fecal transplantation effective at providing relief to C. diff patients

Frozen fecal transplantation effective at providing relief to C. diff patients

Frozen fecal transplantation is effective at providing relief to Clostridium difficile (C. diff) patients, according to a new study co-authored by University of Guelph researchers. [More]
Researcher seeks to identify probiotic mixes to treat Clostridium difficile infections

Researcher seeks to identify probiotic mixes to treat Clostridium difficile infections

Antibiotics that fight infection can adversely affect the digestive tract and give destructive bacteria a chance to flourish, said assistant professor of veterinary and biomedical sciences Joy Scaria of South Dakota State University. His research seeks to identify probiotic mixes to treat intestinal infections, such as Clostridium difficile. [More]
Discoveries could lead to development of novel therapies to prevent C. diff infection

Discoveries could lead to development of novel therapies to prevent C. diff infection

Researchers at Vanderbilt University Medical Center have obtained the crystal structure of a toxin from the bacterium Clostridium difficile ("C. diff") -- the leading cause of hospital-acquired diarrhea in the United States. [More]
Common antibiotics can promote C. diff infections by killing off bile acid-altering microbes

Common antibiotics can promote C. diff infections by killing off bile acid-altering microbes

New research from North Carolina State University and the University of Michigan finds that bile acids which are altered by bacteria normally living in the large intestine inhibit the growth of Clostridium difficile, or C. diff. C. diff is a harmful bacterium that can cause painful and sometimes fatal infections. [More]
Candidiasis needs to be treated early, aggressively to help vulnerable hospitalized patients

Candidiasis needs to be treated early, aggressively to help vulnerable hospitalized patients

One of the most common causes of healthcare-associated infections, candidiasis is a serious, life-threatening fungal infection that needs to be treated early, aggressively and appropriately, note updated guidelines released by the Infectious Diseases Society of America and published in the journal Clinical Infectious Diseases. [More]
Bacteriophage therapy: an alternative to antibiotics? An interview Professor Clokie

Bacteriophage therapy: an alternative to antibiotics? An interview Professor Clokie

A phage is a virus that infects a bacterium. People often get very confused about what the difference is between a virus and a bacterium. A virus, like a bacterium, is also a microorganism, but unlike bacteria, it needs to have a host to be able to replicate and propagate. [More]
Loyola professor receives prestigious 2015 Marion Spencer Fay Award

Loyola professor receives prestigious 2015 Marion Spencer Fay Award

Loyola University Chicago Professor Katherine L. Knight, PhD, one of the nation's leading immune system researchers, has received the prestigious 2015 Marion Spencer Fay Award. [More]
Rebiotix's RBX2660 receives FDA Breakthrough Therapy designation for treatment of recurrent C diff infection

Rebiotix's RBX2660 receives FDA Breakthrough Therapy designation for treatment of recurrent C diff infection

Rebiotix Inc. today announced that U.S. Food and Drug Administration has designated its lead Microbiota Restoration Therapy (MRT) RBX2660 as a Breakthrough Therapy for the treatment of recurrent Clostridium difficile (C diff) infection, a challenging to treat gastrointestinal (GI) infection that causes 29,000 deaths in the U.S. annually. [More]
UV robots help reduce rates of C. diff transmission among cancer inpatients

UV robots help reduce rates of C. diff transmission among cancer inpatients

Robots are capable of all sorts of tasks to help better treat cancer: They connect oncologists to patients remotely, make incisions, staple them shut, deliver "nano" therapies--and they clean rooms. New research from Penn Medicine infection control specialists found that ultraviolet (UV) robots helped reduce the rates transmission of the common bacterial infection known as Clostridium difficile among cancer inpatients - mostly blood cancer patients, a group more vulnerable to hospital-acquired infections - by 25 percent. The interventions also saved about $150,000 in annual direct medical costs. [More]
Advertisement
Advertisement